Drug intelligence / Profile preview

IPSC-GDNKT

Development stage: Preclinical
Lead developer: CytoMed Therapeutics China
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IPSC-GDNKT is an allogeneic, off-the-shelf cell therapy product composed of gamma delta natural killer T (γδ NKT) cells generated from induced pluripotent stem cells (iPSCs) using a proprietary differentiation protocol. Developed by CytoMed Therapeutics through technologies licensed from Accelerate Technologies, IPSC-GDNKT cells possess surface markers and innate cytotoxic properties of both γδ T cells and natural killer (NK) cells, enabling broad-spectrum recognition and killing of cancer cells without the need for genetic modification. These engineered cells function as potent immune effectors—directly killing cancer cells via perforin/granzyme and other cytotoxic pathways, and potentially activating endogenous NK and cytotoxic T cells. IPSC-GDNKT is being advanced for the immunotherapy of both solid and hematological malignancies, with a strategy aimed at scalable, donor-independent manufacturing and application in allogeneic clinical settings.[1][3][7]

Other names: iPSC-γδ NKT celliPSC-gdNKTiPSC-gamma delta NKT cell

Targets

ULBP1 (UL16-binding protein 1)Fas Ligand Pathway

Beyond the preview

Go deeper on IPSC-GDNKT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPSC-GDNKT.

Explore the full profile